IMMUNE-MEDIATED MYOCARDITIS FOLLOWING SINGLE DOSE OF ADJUVANT ATEZOLIZUMAB: DOES BENEFIT OUTWEIGH RISK?
Ashwin S. Kumar(Harvard University), Ana Barac(Inova Fairfax Hospital), Austin Culver(Cleveland Clinic), Allan L. Klein(Cleveland Clinic), Joshua E. Reuss(Georgetown University), Salima Mansoor Ali(Cleveland Clinic), Sarah Mudra(Georgetown University), Amit K. Dey(National Institutes of Health), Alexander A. Rizk(Cleveland Clinic), Harjit Singh(Lovely Professional University), Ankit Agrawal(Northwestern University)
Cited by 1
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
|New England Journal of Medicine|2001|954
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
CT Angiography for Safe Discharge of Patients with Possible Acute Coronary Syndromes
|New England Journal of Medicine|2012|707